ClinicalTrials.gg
RecruitingNCT06238297SNAPUpdated May 30, 2025

Rapid De-escalation of Anti-MRSA Therapy Guided by S. Aureus Nares Screening in Case of Pneumonia

An interventional study of MRSA nasal swab based de-escalation in Pneumonia, Bacterial, sponsored by University of Bari Aldo Moro. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-30.

Sponsored by University of Bari Aldo Moro · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 5 months ago, but the record still lists the study as recruiting.
  • Started May 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Pneumonia, Bacterial with a site in Italy — 5 open to participants now, 5 under way, 1 of them phase 3. Pneumonia, Bacterial · Italy.

Started
2024
with 1 other
No phase
Only one
of the 10
Registered
6th of 10
by date
Lead sponsor
1 of 10
University of Bari Aldo Moro

Among the 10 studies in Pneumonia, Bacterial with a site in Italy, this one is one of 2 that started in 2024, is the only one with no phase, and was the 6th registered.

Pneumonia, Bacterial

153 studies on the registry are indexed under Pneumonia, Bacterial; 27 are open to participants now.

Browse Pneumonia, Bacterial studies →

Open to participants now

5 of the 10 studies in Pneumonia, Bacterial with a site in Italy are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 18 Pneumonia, Bacterial studies recruiting now, 12 (67%) set no upper age limit and 2 (11%) stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Pneumonia, Bacterial with a site in Italy, or all of them as a file.
02

Study summary

The current IDSA/ATS guidelines recommend Linezolid and Vancomycin for MRSA coverage in hospitalized patients with pneumonia, which is common clinical practice in Italy. However, a nasal PCR-assay for MRSA has a high negative predictive value and can facilitate rapid antibiotic de-escalation, thereby avoiding unnecessary anti-MRSA treatments. The indiscriminate use of these drugs has contributed to the emergence of resistant S. aureus strains and has led to significant adverse effects, without providing any survival benefits. Additionally, it has increased hospital stays and associated costs. The proposed study aims to use this diagnostic tool to shorten empirical anti-MRSA treatment duration in pneumonia patients, focusing on reducing antimicrobial therapy days while measuring in-hospital mortality, length of stay and adverse drug event incidence.

Read the detailed description

BACKGROUND On the basis of current IDSA/ATS guidelines antimicrobial agents such as Linezolid and Vancomycin are commonly used in hospitalized patients as an empirical treatment in community acquired pneumonias (CAPs) particularly in hospital-acquired pneumonias (HAPs) and ventilator associated pneumonias (VAPs), suggesting the empiric use of such anti-MRSA agents for patients with specific risk factors (e.g. recent hospitalization, exposure to parenteral antibiotics and/or previous isolation of these organisms, in particular from the respiratory tract) while obtaining culture data.

According to the 2023 annual report of the European Antibiotic Resistance Surveillance System (EARSS) there is a high prevalence of MRSA throughout the European territory, however, even in countries with high endemicity, the presence of MRSA has remained stable in the last years. In Italy, according to the National Antibiotic-Resistance Surveillance System AR-ISS, in 2021 the percentage of blood isolates MRSA isolates showed a reduction (29.9%) in the national territory, standing, however, at 33.6% in the Puglia region, a percentage higher than the European.

In patients with pneumonia, the nasal PCR-assay for MRSA has a high negative predictive value (NPV), with the crucial implication that a negative result can be used to guide the antibiotic de-escalation, avoiding an improper empiric use of the anti-MRSA therapy. Data supporting the clinical validity of the use of the nasal swab for MRSA as a diagnostic tool for pneumonia are robust, in this regard, as stated by the IDSA/ATS guidelines and supported by numerous retrospective studies, anti-MRSA treatment can be avoided in case of negative result, especially in non-severe CAP, thus preventing the misuse of anti-MRSA drugs.

The indiscriminate use of these drugs over time has considerably led to the selection of resistant strains of S. aureus such as Vancomycin-intermediate Staphylococcus aureus (VISA), heterogeneous VISA (hVISA) and Vancomycin-resistant Staphylococcus aureus (VRSA). Furthermore, the high risk of adverse events given by the empirical use of anti-MRSA drugs should also be noted including, among others, nephrotoxicity and ototoxicity with vancomycin and bone marrow suppression and peripheral neuropathy with linezolid, without a gain in terms of survival and with longer hospitalization stays.

In addition, the systematic use of such drugs is associated with an increase in hospital costs, where the PCR assay for MRSA has a relevant role. According to a study conducted by the Stanford University in 2021, enabling antibiotic de-escalation within 24h, its use has of facts led to a cost saving of vancomycin of $40.33 per patient.

On these assumptions, it is clear that using the nasal swab for MRSA in pneumonia diagnosis avoids the use of expensive drugs giving a large impact on health costs, while also reducing the risk of iatrogenic toxicity, hospital stay days and the duration of ventilation in VAPs.

The aim of our study is to implement the use of the nasal swab for MRSA as a diagnostic tool reducing the duration of the empirical anti-MRSA treatment in the population of hospitalized patients with pneumonia.

METHODS AND PROCEDURES. This will be a prospective, randomized single-center controlled study conducted in the Azienda Consorziale Policlinico di Bari.

The minimum sample size is 38 patients per group, for a total of 76 subjects, calculated assuming a standard deviation of 10, a power of 90% and a type I error of 5%.

The study will involve two phases: a first phase of enrollment of the subjects, with the collection of informed consent, of the anamnestic and personal data, a phase of randomization with consequent execution, within 48h from the start of the anti-MRSA empirical therapy, of the nasal swab for MRSA in the experimental group of patients. In a second step, the research assistants will continue the follow-up of the subject with cessation of the empiric treatment in case of negative result of the swab.

The implementation of these steps will be ensured by the performance of the tasks foreseen for each unit. Each clinical unit will:

  • Enroll patients and collect demographic, clinical, and biochemical data at baseline, as well as ensure their management according to guidelines and scientific evidence for the entire duration of the follow-up;
  • Perform a nasal swab for MRSA in patients in the experimental group and discontinue the empirical anti-MRSA therapy if the nasal swab result is negative.
  • For both arms, follow-up visits will be on day 2, 5, 7, 14, and 28 relative to the enrollment visit (day 0). At the control visits, data will be collected on the clinical course of pneumonia and laboratory tests. After discharge, the visit can also be conducted by telephone.

For more precision, eligibility criteria and primary and secondary outcomes descriptions are fully detailed in the corresponding sections.

TIMELINE The research project will have a duration of 12 months following the approval of the Ethics Committee of the University of BarI.

STATISTICAL ANALYSIS The sample size is estimated based on the main outcome measure (duration of antibiotic intake), which the investigators assume to have an average of 10 days in the control group and 2 days in the experimental group. Assuming a standard deviation of 10, a power of 90%, and a type I error of 5%, it is necessary to enroll a minimum of 34 patients per group (thus a total of 68 patients) in order to demonstrate a reduction from 10 to 2 days in the duration of antibiotic intake. To this is added an estimated 10% of cases lost to follow-up, resulting in a final sample size of 76 patients.

The statistical analysis will be conducted according to the intention-to-treat approach. In case of contamination between the two treatment groups (which is considered unlikely in this case), an analysis per protocol will also be performed and the conclusions of the study will take into account the results of both. Numerical data will be summarized as mean and standard deviation, while categorical data as absolute and relative frequency. The two groups will be compared with the Student's t-test (numerical data) and with the Chi-Square test or Fisher's test (categorical data). The effects will be expressed as mean difference or relative risk, accompanied by a 95% confidence interval. All tests will be two-tailed, and a p-value lower than 0.05 will be considered significant. The statistical analysis will be carried out with R software version 4.3 (R Foundation for Statistical Computing, Vienna, Austria).

03

Conditions studied

  • Pneumonia, Bacterial

Keywords

  • MRSA
  • Antimicrobial stewardship
  • Randomized trial
  • Pneumonia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects 18 years or older.
  • Patients hospitalized at the Azienda Consorziale Policlinico di Bari;
  • Clinical diagnosis of CAP/HAP/VAP;
  • Commitment by the prescribing physician to set an anti-MRSA antibiotic therapy in empirical
  • Enrollement within 48h from the beginning of the empirical anti-MRSA therapy.

Exclusion criteria

Exclusion Criteria:

  • Febrile neutropenia or severe immunodeficiency;
  • Chronic airway infection (eg cystic fibrosis);
  • Suspect of extrapulmonary infection by MRSA
  • Refusal by the patient or legal guardian;
  • Refusal by the physician in charge of the patient to perform antibiotic de-escalation based on the result of the nasal swab;
  • Enrollment after 48 hours from the beginning of the empirical anti-MRSA therapy.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
76 participants (estimated)

Study arms

  • Experimental
    Intervention

    Patients included into the intervention arm will undergo a nasal swab for MRSA and empirical anti-MRSA therapy will be discontinued f the nasal swab result is negative.

    Diagnostic Test: MRSA nasal swab based de-escalation

  • No intervention
    Control

    Patients randomized into the control arm will continue pneumonia treatment as per standard of care

Interventions

  • Diagnostic testMRSA nasal swab based de-escalation

    Patients included into the intervention arm will undergo a nasal swab for MRSA and empirical anti-MRSA therapy will be discontinued f the nasal swab result is negative.

06

What researchers measure

Primary outcomes

  1. Duration of antibiotic intake

    Time frame: From day zero to day 28

Secondary outcomes

  1. In-hospital mortality

    Time frame: From day zero to day 28

  2. Hospital lenght-of stay

    Time frame: From day zero to day 28 or until discharge

  3. Incidence of severe pneumonia requiring mechanical ventilation

    Time frame: From day zero to day 28 or until discharge

  4. Incidence of drug-related adverse outcomes

    Time frame: From day zero to day 28

  5. Hospital costs

    Time frame: From day zero to day 28 or until discharge

07

Study locations

1 of 1 sites recruiting
  • Università di Bari "Aldo Moro"
    Bari, 70124, Italy
    Recruiting
08

References and documents

Publications

  • Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, Cooley LA, Dean NC, Fine MJ, Flanders SA, Griffin MR, Metersky ML, Musher DM, Restrepo MI, Whitney CG. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019 Oct 1;200(7):e45-e67. doi: 10.1164/rccm.201908-1581ST. PubMed 31573350 ↗
  • Dangerfield B, Chung A, Webb B, Seville MT. Predictive value of methicillin-resistant Staphylococcus aureus (MRSA) nasal swab PCR assay for MRSA pneumonia. Antimicrob Agents Chemother. 2014;58(2):859-64. doi: 10.1128/AAC.01805-13. Epub 2013 Nov 25. PubMed 24277023 ↗
  • Parente DM, Cunha CB, Mylonakis E, Timbrook TT. The Clinical Utility of Methicillin-Resistant Staphylococcus aureus (MRSA) Nasal Screening to Rule Out MRSA Pneumonia: A Diagnostic Meta-analysis With Antimicrobial Stewardship Implications. Clin Infect Dis. 2018 Jun 18;67(1):1-7. doi: 10.1093/cid/ciy024. PubMed 29340593 ↗
  • Mergenhagen KA, Starr KE, Wattengel BA, Lesse AJ, Sumon Z, Sellick JA. Determining the Utility of Methicillin-Resistant Staphylococcus aureus Nares Screening in Antimicrobial Stewardship. Clin Infect Dis. 2020 Aug 22;71(5):1142-1148. doi: 10.1093/cid/ciz974. PubMed 31573026 ↗
  • Dadgostar P. Antimicrobial Resistance: Implications and Costs. Infect Drug Resist. 2019 Dec 20;12:3903-3910. doi: 10.2147/IDR.S234610. eCollection 2019. PubMed 31908502 ↗
  • Meng L, Pourali S, Hitchcock MM, Ha DR, Mui E, Alegria W, Fox E, Diep C, Swayngim R, Chang A, Banaei N, Deresinski S, Holubar M. Discontinuation Patterns and Cost Avoidance of a Pharmacist-Driven Methicillin-Resistant Staphylococcus aureus Nasal Polymerase Chain Reaction Testing Protocol for De-escalation of Empiric Vancomycin for Suspected Pneumonia. Open Forum Infect Dis. 2021 Mar 4;8(4):ofab099. doi: 10.1093/ofid/ofab099. eCollection 2021 Apr. PubMed 34386545 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Jun 2025, 12 months after the start.

Of 19 interventional studies with no phase under Pneumonia, Bacterial, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2024
First posted
Feb 2, 2024
StartActual
May 6, 2024
Primary completionEst.
Jun 3, 2025
CompletionEst.
Jun 30, 2025
Last update
May 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06238297
Lead sponsor
University of Bari Aldo Moro
Responsible party
Francesco Vladimiro Segala (Principal investigator, University of Bari Aldo Moro) — Principal investigator
First posted
Feb 2, 2024
Start date
May 6, 2024
Primary completion
Jun 3, 2025 (estimated)
Completion
Jun 30, 2025 (estimated)
Last update
May 30, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion